0001193125-24-068672.txt : 20240315 0001193125-24-068672.hdr.sgml : 20240315 20240315093302 ACCESSION NUMBER: 0001193125-24-068672 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240314 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Better Therapeutics, Inc. CENTRAL INDEX KEY: 0001832415 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39864 FILM NUMBER: 24752785 BUSINESS ADDRESS: STREET 1: 548 MARKET ST. #49404 CITY: SAN FRANCISCO STATE: CA ZIP: 94101 BUSINESS PHONE: 415-887-2311 MAIL ADDRESS: STREET 1: 548 MARKET ST. #49404 CITY: SAN FRANCISCO STATE: CA ZIP: 94101 FORMER COMPANY: FORMER CONFORMED NAME: Mountain Crest Acquisition Corp II DATE OF NAME CHANGE: 20201116 8-K 1 d812144d8k.htm 8-K 8-K
NASDAQ false 0001832415 0001832415 2024-03-14 2024-03-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2024 (March 14, 2024)

 

 

BETTER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39864   85-3472546

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

548 Market Street #49404  
San Francisco, California   94104
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (415) 887-2311

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock   BTTX   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on December 14, 2023, Better Therapeutics, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and market value of listed securities requirements for continued listing on The Nasdaq Capital Market, the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). On December 21, 2023, the Company requested a hearing before the Panel, which temporarily stayed the suspension of trading and delisting of the Company’s common stock. The hearing occurred on March 14, 2024, and the Company voluntarily requested a delisting of its securities at the hearing.

As a result, Nasdaq issued a notice to the Company that its shares will be suspended from trading at the open of business on March 18, 2024, and Nasdaq will file a Form 25 Notification of Delisting with the Securities and Exchange Commission after applicable appeal periods have lapsed. The Company further intends to file a Form 15 with the Securities and Exchange Commission to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended.

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Directors

On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof. None of these resignations resulted from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Termination of Officers

On March 14, 2024, Dr. Mark Berman and Kristyn Wynholds were each notified by the Company of termination of their positions as Chief Medical Officer and Chief Product Officer, respectively. On March 14, 2024, Frank Karbe resigned from his position as CEO, President, Treasurer and Secretary.

Election of Director and Officer

On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company’s CEO, President, Treasurer, Secretary, and sole member of the Board. Mr. Jalbert will also serve as the Company’s principal executive officer, and as its principal financial officer and principal accounting officer. Mr. Jalbert’s term as director shall expire upon the election and qualification of his successor. Mr. Jalbert has not been appointed to any committee of the Board and as of the date hereof is not expected to be appointed to any committee of the Board.

 

Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in their wind-down phases.

In connection with his appointment, Mr. Jalbert will be compensated in the amount of $33,333 per year. There is no arrangement or understanding pursuant to which Mr. Jalbert was appointed to the Board. There are no family relationships between Mr. Jalbert and any director or executive officer of the Company, and Mr. Jalbert has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    Better Therapeutics, Inc.
Dated: March 15, 2024     By:  

/s/ Craig Jalbert

    Name:   Craig Jalbert
    Title:   Chief Executive Officer
 EX-101.SCH 2 bttx-20240314.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 bttx-20240314_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 bttx-20240314_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 14, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001832415
Document Type 8-K
Document Period End Date Mar. 14, 2024
Entity Registrant Name BETTER THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39864
Entity Tax Identification Number 85-3472546
Entity Address, Address Line One 548 Market Street #49404
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code (415)
Local Phone Number 887-2311
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol BTTX
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bttx-20240314.xsd bttx-20240314_lab.xml bttx-20240314_pre.xml d812144d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d812144d8k.htm": { "nsprefix": "bttx", "nsuri": "http://www.bettertherapeuticsInc.com/20240314", "dts": { "schema": { "local": [ "bttx-20240314.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "bttx-20240314_lab.xml" ] }, "presentationLink": { "local": [ "bttx-20240314_pre.xml" ] }, "inline": { "local": [ "d812144d8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-14_to_2024-03-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d812144d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-14_to_2024-03-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d812144d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.bettertherapeuticsInc.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-24-068672-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-068672-xbrl.zip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d812144d8k_htm.xml IDEA: XBRL DOCUMENT 0001832415 2024-03-14 2024-03-14 NASDAQ false 0001832415 8-K 2024-03-14 BETTER THERAPEUTICS, INC. DE 001-39864 85-3472546 548 Market Street #49404 San Francisco CA 94104 (415) 887-2311 false false false false Common Stock BTTX true false